ADAKVEO

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Estonia, Finland, France, Ireland, Israel, Lithuania, Poland, UK.

Active ingredients

The drug ADAKVEO contains one active pharmaceutical ingredient (API):

1	Crizanlizumab UNII L7451S9126 - CRIZANLIZUMAB
	Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1.
	Read more about Crizanlizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADAKVEO Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AX01		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526520070096307
EE	Ravimiamet	1831441
FI	Lääkealan turvallisuus- ja kehittämiskeskus	181522
FR	Base de données publique des médicaments	62004984
GB	Medicines & Healthcare Products Regulatory Agency	396539
IL	מִשְׂרַד הַבְּרִיאוּת	8757
LT	Valstybinė vaistų kontrolės tarnyba	1091344
PL	Rejestru Produktów Leczniczych	100446201
US	FDA, National Drug Code	0078-0883